Bifogade filer
PDF
NOVEMBER 2024 - JANUARY 2025
| Net sales | 6 481 (4 873) KSEK |
| Operating result before depreciation (EBITDA) | -987 (-3 179) KSEK |
| Net result | -2 681 (-5 152) KSEK |
| Earnings per share | -0.08 (-0.21) SEK |
| Gross margin | 76 (72) % |
MAY 2024 - JANUARY 2025
| Net sales | 10 796 (8 824) KSEK |
| Operating result before depreciation (EBITDA) | -8 510 (-9 568) KSEK |
| Net result | -12 280 (-14 826) KSEK |
| Earnings per share | -0.34 (-0.58) SEK |
| Gross margin | 71 (73) % |
IN SHORT
- Sales grew significantly for both Q3 and YTD, outperforming the FY results of the previous year.
- Gross margin continues to be strong, even slightly above planned levels (+4pp).
- Overall costs remain stable and as per plan; higher admin costs (capital raise connected) vs. lower R&D expenses.
- The absolute key to transforming the Company, both short-term and long-term, is a significant increase in sales, which is expected due to a strong pipeline & company potential.
CEO Commentary
Having recently taken on the role of acting CEO at PHI, my primary focus is execution-translating the Company's potential into tangible results. We have a strong foundation built on deep technical expertise and a clear commitment to advancing regenerative medicine. Now, it's time to maximize that potential.
Our path forward is clear: be the best at what we know best. This means focusing on cutting-edge imaging technology that empowers cell research and therapy, supported by a strong distributor network and strategic partnerships. Our recent financial performance demonstrates that we are moving in the right direction, with growing sales and a strong gross margin. However, we must accelerate further, ensuring our innovations reach the market at scale.
With a committed team, solid industry relationships, and a clear mission, we are ready to take PHI to the next level. The focus now is on execution and delivering on our promises-because the opportunity ahead is too great not to seize.
Ivan Jurkovic, CEO